The emerging research on cagrilintide combined with semaglutide (CagriSema) represents one such approach, adding amylin receptor agonism to GLP-1 for enhanced results
BPC-157s effects on multiple neurotransmitter systems create theoretical interaction points with psychiatric medications, yet interactions are not well studied. Particular concerns include serotonin syndrome risk when combined with SSRIs (since BPC-157 modulates serotonin in complex regional patterns), unpredictable effects on dopaminergic medications (antipsychotics, ADHD treatments, Parkinsons medications), and unknown interactions with benzodiazepines despite the animal studies showing tolerance prevention
They can help stabilize blood sugar by enhancing glucose-dependent insulin secretion , reducing glucagon , and slowing digestion , which can reduce spikes after meals
If results are positive, it could support the advancement of oral DHT-liraglutide to a Phase I trial
Full dosing lives in the KLOW dosage protocol guide